Immunomedics' trodelvy shows 27% response rate in urothelial cancer [Seeking Alpha]
IMMUNOMEDICS (IMMU)
Last immunomedics earnings: 2/27 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
immunomedics.com/2017/immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium
Company Research
Source: Seeking Alpha
HealthcareImmunomedics' trodelvy shows 27% response rate in urothelial cancerSep. 21, 2020 9:05 AM ET|Immunomedics, Inc. (IMMU)Vandana Singh(NASDAQ:announced positiveResults confirmed the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC who progressed on both platinum-based chemotherapy and checkpoint inhibitors.As of data cutoff on May 18, 8 of the 31 responders have an ongoing response and remain on treatment.Trodelvy achieved a 27% overall response rate and a 5.9-month median duration of response in heavily-pretreated mUC patients. Median progression-free survival was 5.4 months with median overall survival of 10.5 months.On safety front, Trodelvy demonstrated to be tolerable. Serious/severe treatment-related adverse events were mostly hematologic and gastrointestinal related, including neutropenia, low level of type of white blood cells called neutrophils (34%) and diarrhea (10%). Seve
Show less
Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMU alerts
High impacting IMMUNOMEDICS news events
Weekly update
A roundup of the hottest topics